黄芪注射液与胰激肽原酶片对早期糖尿病肾病疗效观察

Therapeutic effect of Huangqi injection and pancreatic kininogenase tablets on the early stage diabetic nephropathy

目的:评价黄芪注射液与胰激肽原酶片治疗早期糖尿病肾病患者的疗效和安全性。方法:将85例早期糖尿病肾病患者随机分成2组,在糖尿病饮食控制、体育锻炼及根据病情给予口服降糖药物或/和胰岛素治疗基础上,治疗组加用黄芪注射液与胰激肽原酶片治疗4周,观察治疗前后尿微量白蛋白与24h尿蛋白定量和不良反应。结果:治疗组治疗后尿微量白蛋白与24h尿蛋白定量明显降低,差异具有极显著性(P<0.01),对照组治疗后无明显差异(P>0.05),组间比较差异具有极显著性(P<0.01)。无明显药物不良反应。结论:黄芪注射液与胰激肽原酶片治疗早期糖尿病肾病患者疗效好,安全合理。

OBJECTIVE To evaluate the efficacy and safety of Huangqi injection and Pancreatic kininogenase tablets in treating early stage diabetic nephropathy. METHODS 85 early stage diabetic nephropathy patients were divided randomly into 2 groups, In addition to dietary control, physical exercise, and administrating with oral anti-diabetic drugs according to the condition and/or insulin treatment, Huanhqi injection and pancreatic kininogenase tablets were given to the patients of the test group for 4 weeks, Micro-quantity urine albumin, 24 h quantity of urine protein and ADR were observed before and after the treatment. RESULTS The urine micro-quantity albumin and quantity of 24 h urine protein of the test group decreased after treatment with significant difference （P〈0.01）, no significant difference was found of the control group （P〉0. 05 ）, the difference between groups was significant, too（P〈0. 01 ）. No distinct ADR was found. CONCLUSION Huangqi injection and pancreatic kininogenase tablets are effective and safe in the treatment of early stage biabetic nephropathy.